Salud financiera de hoja de balance de Cyclerion Therapeutics

Salud financiera controles de criterios 4/6

Cyclerion Therapeutics tiene un patrimonio de los accionistas total de $11.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $13.4M y $2.1M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$7.57m
Patrimonio	US$11.29m
Total pasivo	US$2.09m
Activos totales	US$13.37m

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03

Recent updates

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20

Cyclerion Therapeutics reports Q3 results

Nov 05

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($8.0M) de CYCN superan a sus pasivos a corto plazo ($2.1M).

Pasivo a largo plazo: CYCN no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: CYCN está libre de deudas.

Reducción de la deuda: CYCN no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CYCN tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: CYCN tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 22.8% cada año.

Salud financiera de hoja de balance de Cyclerion Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Recent updates

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

New major risk - Financial position

First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022)

New major risk - Market cap size

Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding

High number of new and inexperienced directors

J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021)

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

Price target decreased to US$4.00

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Consensus revenue estimates fall by 54%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia

Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

High number of new directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Progress

Price target increased to US$10.50

High number of new directors

Consensus revenue estimates fall by 49%

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Full year 2021 earnings: EPS and revenues miss analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Updates

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020)

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Independent Director Kevin Churchwell has left the company

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020)

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021

Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value Index

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion climbs on a series of insider purchases

Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris Partners

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CEO & Director recently bought US$1.7m worth of stock

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020)

Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes

Cyclerion updates on clinical trial progress at webinar

Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical Officer

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019)

Earnings beat expectations

New 90-day high: US$3.61

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

New 90-day high: US$3.60

Cyclerion Therapeutics +10.5% after prelim reports

President & Chief Scientific Officer notifies of intention to sell stock

President & Chief Scientific Officer recently sold US$61k worth of stock

Cyclerion Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective January 1, 2021

Cyclerion Therapeutics announces promotions

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Chief Innovation Officer recently bought US$316k worth of stock

Third quarter 2020 earnings released: US$0.59 loss per share

Revenue and earnings beat expectations

Cyclerion Therapeutics reports Q3 results

Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects